Mechanisms of pleurodesis

Respiration

Volumn 83, Issue 2, 2012, Pages 91-98

  Rodriguez Panadero, Francisco ^a,b,c   Montes Worboys, Ana ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

Coagulation; Effusions; Pleurodesis; Sclerosing agents; Systemic inflammation; Talc

Indexed keywords

DOXYCYCLINE; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR; POVIDONE IODINE; SILVER NITRATE; TALC; TRANSFORMING GROWTH FACTOR BETA;

ANTITUMOR GENE; APOPTOSIS; BREAST CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; DYSPNEA; FIBRINOLYSIS; FOLLOW UP; HOSPITALIZATION; HUMAN; INFLAMMATION; LUNG CANCER; MESOTHELIUM; MULTICENTER STUDY (TOPIC); PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS; REVIEW; SURVIVAL; SURVIVAL TIME; THORACOCENTESIS; THORACOSCOPY; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME;

DYSPNEA; FIBRINOLYSIS; HUMANS; PLEURA; PLEURAL CAVITY; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; SCLEROSING SOLUTIONS; TALC;

EID: 84856483032     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000335419     Document Type: Review

References (61)

1. Froudarakis ME: New challenges in medical thoracoscopy. Respiration 2011;82:197-200.
2. Rodriguez-Panadero F: Medical thoracoscopy. Respiration 2008;76:363-372.
3. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al: Management of malignant pleural effusions. Eur Respir J 2001;18:402-419.
4. Huggins JT, Doelken P, Sahn SA: The unexpandable lung. F1000 Med Rep 2010;2:77.
5. Hartman DL, Antony VB, Hott JW, Godbey SW, Yu L, Rodriguez Panadero F: Thoracoscopic talc insufflation increases pleural fluid IL-8 levels in patients with malignant pleural effusions. Am J Respir Crit Care Med 1994;149(suppl 2): A974.
6. Xie C, Teixeira LR, McGovern JP, Light RW: Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Crit Care Med 1998;157:1441-1444.
7. Mutsaers SE, Prele CM, Brody AR, Idell S: Pathogenesis of pleural fibrosis. Respirology 2004;9:428-440.
8. Agrenius V, Chmielewska J, Widström O, Blombäck M: Increased coagulation activity of the pleura after tube drainage and quinacrine instillation in malignant pleural effusion. Eur Respir J 1991;4:1135-1139.
9. Agrenius V, Chmielewska J, Widström O, Blombäck M: Pleural fibrinolytic activity is decreased in inflammation as demonstrated in quinacrine pleurodesis treatment of malignant pleural effusion. Am Rev Respir Dis 1989;140:1381-1385.
10. Rodriguez-Panadero F, Segado A, Martin Juan J, Ayerbe R, Torres Garcia I, Castillo J: Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 1995;151:785-790.
11. Antonangelo L, Vargas FS, Teixeira LR, Acencio MM, Vaz MA, Filho MT, Marchi E: Pleurodesis induced by talc or silver nitrate: evaluation of collagen and elastic fibers in pleural remodeling. Lung 2006;184:105-111.
12. Montes JF, Garcia-Valero J, Ferrer J: Evidence of innervation in talc-induced pleural adhesions. Chest 2006;130:702-709.
13. Antony VB, Nasreen N, Mohammed KA, Sriram PS, Frank W, Schoenfeld N, et al: Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest 2004;126:1522-1528.
14. Jantz MA, Antony VB: Pathophysiology of the pleura. Respiration 2008;75:121-133.
15. Rodriguez Panadero F, Gómez Izquierdo L, Martin Juan J, Borderas F, Sánchez JF, Segura DI: The balance between expression of plasminogen activators and their inhibitor (PAI-1) in pleural tissue is associated to outcome of talc pleurodesis. Am J Resp Crit Care Med 1997;155:A739.
16. Psathakis K, Calderon-Osuna E, Romero-Romero B, Martín-Juan J, Romero-Falcón A, Rodríguez-Panadero F: The neutrophilic and fibrinolytic response to talc can predict the outcome of pleurodesis. Eur Respir J 2006;27:817-821.
17. Rodriguez-Panadero F, Antony VB: Pleurodesis. State of the art. Eur Respir J 1997;10:1648-1654.
18. Marchi E, Vargas FS, Acencio MM, Antonangelo L, Genofre EH, Teixeira LR: Evidence that mesothelial cells regulate the acute inflammatory response in talc pleurodesis. Eur Respir J 2006;28:929-932.
19. Sahn SA, Good JT Jr: Pleural fluid pH in malignant effusions: diagnostic, prognostic and therapeutic implications. Ann Intern Med 1988;108:345-349.
20. Rodriguez-Panadero F, Lopez Mejias J: Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989;139:663-667.
21. Sanchez-Armengol A, Rodriguez-Panadero F: Survival and talc pleurodesis in metastatic carcinoma revisited. Report on 125 cases. Chest 1993;104:1482-1485.
22. Rodriguez-Panadero F, Romero-Romero B: Management of malignant pleural effusions. Curr Opin Pulm Med 2011;17:269-273.
23. Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F: Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998;65:108-113.
24. Aelony Y, Yao JF, King RR: Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage. Respiration 2006;73:334-339.
25. Antony VB, Hott JW, Kunkel SL, Godbey SW, Burdick MD, Strieter RM: Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. Am J Respir Cell Mol Biol 1995;12:581-588.
26. Hartman DL, Harper-Allen PJ, Godbey SW, Hott JW, Yu L, Antony VB: Phagocytosis of talc particles by human pleural mesothelial cells (HPMC) correlates with IL-8 production. Am J Respir Crit Care Med 1994;148:A845.
27. Antony VB, Rothfuss KJ, Godbey SW, Sparks JA, Hott JW: Mechanism of tetracycline hydrochlorideinduced pleurodesis: tetracycline hydrochloride- stimulated mesothelial cells produce a growth factor-like activity for fibroblasts. Am Rev Respir Dis 1992;146:1009-1013.
28. Godbey SW, Holm KA, Yu L, Hott JW, Rodriguez-Panadero F, Antony VB: Role of mesothelial cells in pleural fibrosis following successful talc poudrage: identification of basic fibroblast growth factor (FGF-2) in pleural fluids. Am J Respir Crit Care Med 1995;151:A353.
29. 2 produces an excellent pleurodesis in rabbits. Am J Respir Crit Care Med 2000;162:98-104.
30. 2 induces pleurodesis significantly faster than talc. Am J Respir Crit Care Med 2001;163(3 pt 1):640-644.
31. Lee YC, Lane KB, Zoia O, Thompson PJ, Light RW, Blackwell TS: Transforming growth factor-beta induces collagen synthesis without inducing IL-8 production in mesothelial cells. Eur Respir J 2003;22:197-202.
32. Kolschmann S, Ballin A, Gillissen A: Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 2005;128:1431-1435.
33. Viallat JR, Rey F, Astoul P, Boutin C: Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996;110:1387-1393.
34. Bielsa S, Hernandez P, Rodriguez-Panadero F, Taberner T, Salud A, Porcel JM: Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung 2011;189:151-155.
35. Shaw P, Agarwal R: Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004;1: CD002916.
36. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T: The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006;29:829-838.
37. Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, et al: Phase III intergroup study of talc poudrage vs. talc slurry sclerosis for malignant pleural effusion. Chest 2005;127:909-915.
38. Mañes N, Rodriguez-Panadero F, Bravo JL, Hernández Rodríguez H, Alix Trueba A: Talc pleurodesis: prospective and randomized study. Clinical follow-up. Chest 2000;118(4 suppl):131S.
39. Rodriguez-Panadero F, Jannsen JP, Astoul P: Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion. Eur Respir J 2006;28:409-421.
40. Nasreen N, Mohammed KA, Dowling PA, Ward MJ, Galffy G, Antony VB: Talc induces apoptosis in human malignant mesothelioma cells in vitro. Am J Respir Crit Care Med 2000;161(2 pt 1):595-600.
41. Nasreen N, Mohammed KA, Brown S, Su Y, Sriram PS, Moudgil B, Loddenkemper R, Antony VB: Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J 2007;29:761-769.
42. Neto JD, de Oliveira SF, Vianna SP, Terra RM: Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respirology 2010;15:115-118.
43. Mohsen TA, Zeid AA, Meshref M, Tawfeek N, Redmond K, Ananiadou OG, et al: Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg 2011;40:282-286.
44. Terra RM, Kim SY, Pego-Fernandes PM, Teixeira LR, Vargas FS, Jatene FB: Is silver nitrate pleurodesis for patients with malignant pleural effusion feasible and safe when performed in an outpatient setting? Ann Surg Oncol 2011;18:1145-1150.
45. Porcel JM, Salud A, Nabal M, Vives M, Esquerda A, Rodríguez- Panadero F: Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support Care Cancer 2006;14:475-478.
46. Froudarakis ME, Pataka A, Makris D, Kouliatsis G, Anevlavis S, Sotiriou I, et al: Respiratory muscle strength and lung function in patients undergoing medical thoracoscopy. Respiration 2010;80:220-227.
47. Bosch-Barrera J, Espinós J: Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report. Int Arch Med 2010;3:6.
48. Rinaldo JE, Owens GR, Rogers RM: Adult respiratory distress syndrome following intrapleural instillation of talc. J Thorac Cardiovasc Surg 1983;85:523-526.
49. Rehse DH, Aye RW, Florence MG: Respiratory failure following talc pleurodesis. Am J Surg 1999;177:437-440.
50. Ukale V, Agrenius V, Widström O, Hassan A, Hillerdal G: Inflammatory parameters after pleurodesis in recurrent malignant pleural effusions and their predictive value. Respir Med 2004;98:1166-1172.
51. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ: Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004;170:377-382.
52. Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, et al: Safety of talc poudrage in malignant pleural effusion. Lancet 2007;369:1535-1539.
53. Gonzalez AV, Bezwada V, Beamis JF Jr, Villanueva AG: Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest 2010;137:1375-1381.
54. Ferrer J, Villarino MA, Tura JM, Traveria A, Light RW: Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001;119:1901-1905.
55. Froudarakis ME, Klimathianaki M, Pougounias M: Systemic inflammatory reaction after thoracoscopic talc poudrage. Chest 2006;129:356-361.
56. Genofre EH, Marchi E, Vargas FS: Inflammation and clinical repercussions of pleurodesis induced by intrapleural talc administration. Clinics (Sao Paulo) 2007;62:627-634.
57. Kennedy L, Harley RA, Sahn SA, Strange C: Talc slurry pleurodesis: pleural fluid and histologic analysis. Chest 1995;107:1707-1712.
58. Rodriguez-Panadero F, Segado A, Torres I, Martin J, Sanchez J, Castillo J: Thoracoscopy and talc poudrage induce an activation of the systemic coagulation system. Am J Respir Crit Care Med 1995;151:A357.
59. Rodriguez-Panadero F, Segado A, Martin Juan J, Sánchez J, Calderón E, Castillo J: Activation of systemic coagulation in talc poudrage can be (partially) controlled with prophylactic heparin. Am J Respir Crit Care Med 1996;153:A458.
60. Montes-Worboys A, Rodriguez-Portal JA, Arellano-Orden E, Digón-Pereiras J, Rodriguez-Panadero F: Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis. Eur Respir J 2010;35:160-166.
61. Strange C, Baumann MH, Sahn SA, Idell S: Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease. Am J Respir Crit Care Med 1995;151:508-515.